|
Post by mnholdem on Jul 21, 2015 8:43:08 GMT -5
This is the second of two MannKind Corporation positions that CEO Hakan Edstrom stated (1Q15 earnings call) would be filled this summer:
- VP Business Development
- Chief Operating Officer (that position was posted about 3 weeks ago)
The addition of these two positions seems to argue AGAINST the idea of a buyout of the company as a whole, as it makes it appear that MannKind is serious about developing new Technophere drugs through its pipeline, although this development does NOT rule out the sale of Afrezza (the merits of which I am not debating here).
|
|